Hematologic Oncology | Specialty

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020

Selecting First-Line Therapy for CLL

July 30th 2020

Advances in Frontline Therapy for CLL

July 30th 2020

Impact of COVID-19 on Management of CLL

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

FDA Approval Sought for Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma

July 29th 2020

A biologics license application has been submitted to the FDA for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Dr. Raje on the Effectiveness of Quadruplet Therapies in Multiple Myeloma

July 29th 2020

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

Dr. Palmer on the Incidence of Graft-Versus-Host Disease

July 28th 2020

Jeanne M. Palmer, MD, discusses the prognosis and challenges of predicting graft-versus-host disease in patients who have undergone transplant.

Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases

July 27th 2020

An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib is effective at reducing lung inflammation in patients with severe novel coronavirus 2019, thereby decreasing incidences of mechanical ventilation and death in these patients.

ASCO and ACCC Collaborate to Boost Racial/Ethnic Representation in Cancer Treatment Trials

July 27th 2020

A new collaboration between the American Society of Clinical Oncology and the Association of Community Cancer Centers aims to encourage the enrollment of more racially and ethnically diverse patients with cancer onto clinical trials.

EU Panel Recommends Ibrutinib/Rituximab Combo for Frontline CLL

July 24th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.

Updated Data Confirm Long-Term Benefit With Tafasitamab/Lenalidomide in Relapsed/Refractory DLBCL

July 24th 2020

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Selinexor Triplet Shows Strong Clinical Activity in Relapsed/Refractory Myeloma

July 24th 2020

A triplet regimen comprised of selinexor, daratumumab, and dexamethasone proved to be highly active, inducing deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Shammo Previews the Potential of Pevonedistat Combo in High-Risk MDS

July 23rd 2020

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

Genetic Testing Could Lead to Improved Treatment Decisions, Predicted Outcomes in MPNs, MDS

July 23rd 2020

Mutually exclusive gene combinations were observed between specific subtypes of patients with myelodysplastic syndromes and myeloproliferative neoplasms and most other types of MDS/MPNs that have an impact on patient outcomes.

Ruxolitinib Improves ORR in Steroid-Refractory, Dependent Chronic GVHD

July 23rd 2020

Ruxolitinib was found to demonstrate a superior objective response rate at 24 weeks compared with best available therapy in patients with steroid-refractory or steroid-dependent chronic graft-versus-host-disease, meeting the primary end point of the phase 3 REACH3 trial.

Selinexor Shows Meaningful, Durable Responses Linked With Improved OS in DLBCL

July 23rd 2020

Single-agent selinexor was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy.